摘要
目的:提高以-βhCG为靶抗原的癌症基因疫苗的免疫原性及抗肿瘤效果。方法:构建基因疫苗pCR-HSP65-X10-βhCGCTP37,并将之与细胞因子佐剂GM-CSF合用。通过对其免疫原性和体内抗肿瘤效果的评价来验证方法的可行性。结果:pCR-HSP65-X10-βhCGCTP37基因疫苗能够成功地诱发机体产生抗-βhCG的特异性抗体,并能在体内起到抗肿瘤作用;GM-CSF能有效提高疫苗的免疫原性和抗肿瘤效果。结论:pCR-HSP65-X10-βhCGCTP37有望成为有效的抗肿瘤基因疫苗,GM-CSF可作为抗肿瘤基因疫苗的理想佐剂。
AIM：To improve the immunogenicity and anti-tumor effects of DNA vaccines based on β-hCG as an ideal target antigen to vaccinate against tumors. METHOD： A DNA vaccine pCR-HSP65-X10-13hCGTP37 has been constructed and used to immunize mice combined with GM-CSF as an adjuvant. These approaches were tested by assessing the novel DNA vaccine for its immunogenicity and anti- tumor effects in vivo. RESEULT： pCR-HSP65-X10-βhCGTP37 vaccine could elicit specific immune responses which could inhibit the growth of tumor cells in vivo and GM-CSF could significantly improve the level of specific antibody and the efficacy of DNA vaccination against cancer. CONCLUSION： pCR-HSP65-X10-βhCGCTP37 may be an effective DNA vaccine for the treatment of β-hCG dependent tumors. GM-CSF could be used as a potent adjuvant to naked DNA vaccines especially when encountering a self-tumor antigen with low immunogenicity.
出处
《中国天然药物》
SCIE
CAS
CSCD
2006年第3期234-237,共4页
基金
国家自然科学基金(No.30270298)~~
关键词
基因(DNA)疫苗
异位HCG
细胞因子佐剂
肿瘤
免疫原性
DNA vaccine
Ectopic human chorionic gonadotrophin （ehCG）
Cytokine adjuvant
Tumor
Immunogenicity
